MedWatch

Genmab and Seagen submit cancer drug application to US FDA

The US FDA will evaluate a cervical cancer treatment developed by Genmab and Seagen

Photo: Joost Melis / Genmab / PR

Danish biotech firm Genmab and US biotech firm Seagen have applied for an accelerated approval of the drug candidate tisotumab vedotin at the US Food and Drug Administration, according to a Genmab press release on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs